powerpoint 프레젠테이션 - hanmi · 2017-07-03 · 유방암, 위암 b pd-1/pd-l1 bh2941...
TRANSCRIPT
2
3
4
5
6
In-house 개발된
개량신약 및 복합제 통해
전통 제약 사업에서의
견고한 cash flow 확보
2000년대 초반부터 혁신
R&D 위해 꾸준히 투자
In-house R&D 및
오픈이노베이션 통해
탄탄한 파이프라인 확보
국내, 중국 본업에서의
리더쉽 유지
잠재력 높은 사업
분야로 투자 확대
집중 치료 영역 내
지속적으로 신약
개발하며 글로벌 R&D
파워하우스로 도약
글로벌 신약 개발 통한
성장과 수익 개선
PAST PRESENT FUTURE
Strong focus
on R&D
Partnership
& Alliance
China
Market
+500 R&D experts : Ph.D 64, MS. 305
+800 mil USD invested in the past decade
29 Programs in Pre-clinical & Clinical Development
Broadening global & regional partnership
Open innovation strategy
Synergy between Beijing Hanmi & Hanmi Korea
Competitive R&D supported by global talents
Profitable growth through business diversification
6,740 7,301 7,613
13,175
8,827
910 1,156
1,525 1,871
1,626
-
2,000
4,000
6,000
-
5,000
10,000
15,000
2012 2013 2014 2015 2016
매출 R&D
13.5%
14.2%
18.4%
8
15.8% 20.0%
9
AG
LY
CO
SY
LA
TE
D F
C
AG
LY
CO
SY
LA
TE
D F
C
10
11
Key Features
면역세포를 암세포로 유도
인간 IgG와 유사한 이중항체 형태
우수한 안정성 및 생산 효율성
다양한 파트너링 기회 물색 중
(PENTAMBODY + Novel target)
암세포 면역 세포
P
E
N
T
A M
B
O D
Y
Next-generation bi-specific antibody platform technology
Discovery by Beijing Hanmi with dual immunotherapy & targeted therapy
12
Pentambody applied PD-1/HER2 BsAb
Cell-to-cell association (%) using SK-BR-3 and CHO-PD1 cells by FACS1
1HER2 positive SK-BR-3 stained with CFSE, CHO-PD1 stained with PKH26, Test article 100nM, 30min; 2E (activated hPBMC) : T (HCC827) = 20 : 1, 72hr
면역세포를 암세포로 유도
타 병용 요법 대비 우월한 항암 효과 나타냄
Pentambody applied PD-1/PD-L1 BsAb
Cell cytotoxicity assay using PD-L1 expressed NSCLC cell2
Anti-PD-L1 mAb: IC50 >2,000 pM
Anti-PD-1 mAb: IC50 440 pM
Combination: IC50 50 pM
PD-1/PD-L1 BsAb (BH2941): IC50 10 pM
13
LAPSInsulin Combo HM14220
당뇨
SANOFI
GMB 유전자 세포치료제 HM21001
줄기세포 활용 항암신약
아주대학교 LAPSTriple Agonist
HM15211 비만, 비알코올성 지방간염
LAPSGlucagon Analog HM15136
선천성 고인슐린증
LAPSASB HM15450
뮤코다당체 침착증
FLT3 항암제 HM43239
급성골수성백혈병
PD-1/HER-2 BH2950
유방암, 위암
B
PD-1/PD-L1 BH2941
항암제
B LAPSGLP-2 Analog
HM15910
단장증후군
전임상 임상 2상 임상 3상 임상 1상
LAPSGLP/GCG HM12525A
당뇨/비만
JANSSEN
LAPSInsulin HM12470
당뇨
Pan-RAF저해제 HM95573
고형암
GENENTECH
Oratecan™ 이리노테칸+HM30181A
고형암
ATHENEX
Src/Tubulin KX2-391
고형암
ATHENEX
PD-1/EGFR BH2922
비소세포폐암, 대장암
B
LAPSExd4 Analog 에페글레나타이드
당뇨 & 비만
SANOFI
LAPShGH Efpegsomatropin
성장호르몬 결핍증
올리타 (Olita® *) 올무티닙
폐암
ZAI LAB
Luminate®
Integrin 저해제 망막질환
ALLEGRO
BTK 면역치료제 HM71224
자가면역질환
ELI LILLY
Pan-HER억제제 포지오티닙
고형암
SPECTRUM/LUYE
LAPSGCSF Analog Rolontis™ (Eflapegrastim)
호중구감소증
SPECTRUM
Oraxol™** 파크리탁셀+HM30181A
유방암, 위암
ATHENEX
당뇨/비만
희귀질환
암
자가면역질환
기타
B 북경한미
14
연간 신제품 2-3개 품목 지속적으로 발매
이머징 마켓 파트너링 기회 물색 중
MSD와 ‘로수젯®’ 해외 23개국 수출 계약
4월 ‘베시금’, ‘라본디’, 5월 ‘몬테리진’ 식약처 허가 완료
plan to launch in 2017
*Incrementally Modified Drug **Fixed Dose Combination
Strong focus
on R&D
Partnership
& Alliance
China
Market
+500 R&D experts : Ph.D 64, MS. 305
+800 mil USD invested in the past decade
29 Programs in Pre-clinical & Clinical Development
Broadening global & regional partnership
Open innovation strategy
Synergy between Beijing Hanmi & Hanmi Korea
Competitive R&D supported by global talents
Profitable growth through business diversification
영업 인력 1,000+
Sales & Marketing Manufacturing Beijing R&D center
R&D 인력 150+
16
17
Strong focus
on R&D
Partnership
& Alliance
China
Market
+500 R&D experts : Ph.D 64, MS. 305
+800 mil USD invested in the past decade
29 Programs in Pre-clinical & Clinical Development
Broadening global & regional partnership
Open innovation strategy
Synergy between Beijing Hanmi & Hanmi Korea
Competitive R&D supported by global talents
Profitable growth through business diversification
19
Strong focus
on R&D
Partnership
& Alliance
China
Market
+500 R&D experts : Ph.D 64, MS. 305
+800 mil USD invested in the past decade
29 Programs in Pre-clinical & Clinical Development
Broadening global & regional partnership
Open innovation strategy
Synergy between Beijing Hanmi & Hanmi Korea
Competitive R&D supported by global talents
Profitable growth through business diversification
21
22
23
24
25
26
27
28
600 -7.3%
144 2.1%
147 -2.7%
125 -3.2%
1.0%
11.5%
5.7%
5.8%
29
0%
-11 (-5.0%)
흑자전환
-14 (-6.3%)
흑자전환
-13 (-6.1%)
흑자전환
-21.1% 31.4%
0.9% 13.6%
-19.1% 107.8%
-1.9% 11.2%
-25.6% -28.0%
35.9% 39.5%
-18.8% 8.3%
-15.0% 0%
30
31
32
33
34
35